Ex­clu­sive: ADC start­up Myth­ic re­cruits Jazz ex­ec to lead com­pa­ny; Dyne’s CEO shuf­fle

Myth­ic Ther­a­peu­tics has gone more than a year and a half with­out a CEO.

That’s chang­ing on April 1, as George Eli­ades will join the Waltham, MA-based an­ti­body-drug con­ju­gate biotech. Eli­ades is com­ing from Jazz Phar­ma­ceu­ti­cals, where he’s served as se­nior vice pres­i­dent of cor­po­rate de­vel­op­ment and chief trans­for­ma­tion of­fi­cer for the past three and a half years.

In the in­ter­im, Myth­ic’s CEO du­ties were shared among chief sci­en­tist Bri­an Fiske, COO San­dra Poole and chief de­vel­op­ment of­fi­cer Gilles Gal­lant, ac­cord­ing to a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.